Oncternal And SpringWorks Among Early ASCO Winners And Losers

SpringWorks Declines Despite Positive Results

While the big pharma names dominate the ASCO cancer congress, it is also a chance to shine for emerging small-to-medium biopharma companies.

Nasdaq
Many NASDAQ-listed biotech companies are in need of a share price bounce, which are hard to come by in the current market. • Source: Alamy

The release of data abstracts ahead of the American Society of Clinical Oncology congress always create early winners and losers among those presenting, and for small-to-medium sized companies the share price responses can be extreme.

After this year’s abstracts went live on 26 May, some of the biggest share price decliners were Mirati Therapeutics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas